Feasibility and efficacy of moderate-intensity stereotactic body radiotherapy for ultracentral lung cancer

Case series of treating ultracentral lung tumor using stereotactic body radiothearpy (SBRT)

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

CRIS

Registry ID

KCT0006736

Enrollment

Registered

2021-11-10

Start date

2018-08-15

Completion date

Unknown

Last updated

2023-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Radiation : The stereoctactic body radiotherapy will be performed delivering 45-60Gy in 10 fractions using respiratory tracking system.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients having ultracentral lung tumor treated with stereotactic body radiotherapy in Korea University Ansan Hospital

Exclusion criteria

Exclusion criteria: the patients having other malignancies than ultracentral lung tumor

Design outcomes

Primary

Measure	Time frame
local control, overall survival	—

Secondary

Measure	Time frame
toxicity of grade 2 or higher	—

Countries

Korea, Republic of

Contacts

Public ContactChai Hong Rim

Korea University

crusion3@naver.com+82-31-412-6850

Outcome results